



Amendments to the Claims

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-85 (Canceled).

86. (Currently amended) A method for treating multiple myeloma in a subject comprising administering to the subject a combination of an anti-VLA-4 antibody, or antigen-binding fragment thereof, ~~or antibody homolog~~ and a chemotherapeutic agent, wherein said combination is therapeutically ~~or prophylactically~~ effective to treat multiple myeloma in the subject.

87. (Currently amended) The method of claim 86, wherein the combination comprises a therapeutically ~~or prophylactically~~ effective amount of a first composition comprising the anti-VLA-4 antibody, or antigen-binding fragment thereof, ~~or antibody homolog~~ and a therapeutically ~~or prophylactically~~ effective amount of a second composition comprising the chemotherapeutic agent.

88. (Previously presented) The method of claim 86, wherein the chemotherapeutic agent is selected from the group consisting of melphalan, a bisphosphonate, and thalidomide.

89. (Previously presented) The method of claim 88, wherein the chemotherapeutic agent is melphalan.

90. (Withdrawn) The method of claim 88, wherein the bisphosphonate is selected from the group consisting of ibandronate and pamidronate.

91. (Currently amended) The method of claim 86, 87, 88, 89 or 90, wherein the antibody, or antigen-binding fragment thereof, ~~or antibody homolog~~ is a monoclonal antibody, or antigen-binding fragment thereof ~~or monoclonal antibody homolog~~.

92. (Currently amended) The method of claim 87, 88, 89 or 90, wherein ~~[[an]]~~ the anti-VLA-4 antibody, or antigen-binding fragment thereof, ~~homolog~~ is selected from the group consisting of a human antibody ~~homolog~~, a chimeric antibody ~~homolog~~, a humanized antibody ~~homolog~~, and ~~[[a]]~~ an antigen-binding Fab, Fab', F(ab')<sub>2</sub> or F(v) fragment of a human, chimeric or humanized antibody thereof, ~~is administered~~.

93. (Previously presented) The method of claim 87, 88, 89 or 90, wherein said first composition is administered at a dosage that is lower when administered in combination with said second composition than when not administered in combination with said second composition.

94. (Previously presented) The method of claim 87, 88, 89 or 90, wherein said second composition is administered at a dosage that is lower when administered in combination with said first composition than when not administered in combination with said first composition.

95. (Previously presented) The method of claim 87, 88, 89 or 90, wherein said first composition is administered at a dosage that is lower when administered in combination with said second composition than when not administered in combination with said second composition; and wherein said second composition is administered at a dosage that is lower when administered in combination with said first composition than when not administered in combination with said first composition.

96. (Currently amended) The method of claim 86, 87, 88, 89 or 90, wherein the anti-VLA-4 antibody, or antigen binding fragment thereof, ~~or antibody homolog~~ binds the alpha chain of VLA-4.

97. (Currently amended) The method of claim 86, 87, 88, 89 or 90, wherein the anti-VLA-4 antibody, or antigen-binding fragment thereof, ~~or antibody homolog~~ is a B epitope specific anti-VLA-4 antibody, or antigen-binding fragment thereof ~~or antibody homolog~~.

98. (Currently amended) The method of claim 86, 87, 88, 89 or 90, wherein the ~~administering step comprises administering an~~ anti-VLA-4 antibody, or antigen binding fragment thereof, ~~homolog comprising a humanized light chain and a humanized heavy chain, the light chain and the heavy chain each comprising complementarity determining regions (CDR1, CDR2 and CDR3) from a murine 21.6~~ is a humanized anti-VLA-4 antibody, or antigen-binding fragment thereof.

99. (Canceled)

100. (Currently amended) A method for treating multiple myeloma in a subject comprising administering to the subject a combination of:

(i) [[an]] a humanized anti-VLA-4 antibody, or antigen-binding fragment thereof ~~homolog comprising a humanized light chain and a humanized heavy chain, the light chain and the heavy chain each comprising complementarity determining regions (CDR1, CDR2 and CDR3) from a murine 21.6 anti-VLA-4 antibody; and~~

(ii) melphalan,

wherein said combination is therapeutically ~~or prophylactically~~ effective to treat multiple myeloma in the subject.

101. (Currently amended) A method for treating multiple myeloma in a subject comprising administering to the subject a combination of:

(i) an anti-VLA-4 antibody, or antigen-binding fragment thereof, ~~or antibody homolog~~, wherein the antibody, or antigen-binding fragment thereof, ~~or antibody homolog~~ is a B epitope specific anti-VLA-4 antibody, or antigen-binding fragment thereof ~~or antibody homolog~~; and

(ii) melphalan,

Applicant : Mundy *et al.*  
Serial No. : 10/086,217  
Filed : February 21, 2002  
Page : 5 of 19

Attorney's Docket No.: 10274-063001 / A061CIP2 US

wherein said combination is therapeutically or ~~prophylactically~~ effective to treat multiple myeloma in the subject.